Successful vaccine immunotherapy. An exciting novel approach to cancer treatment.
Global cancer spread to pandemic proportions, has reinforced the importance of disease surveillance and prevention programs, and has provided the stimulus for greater resources in vaccine development. Many reports from phase I or II trials indicate that both partial and complete responses have been observed, with little or no toxicity, in a small proportion of vaccine recipients. Future prospects will be to increase basic knowledge of immunogenic tumor antigens to vaccine administration, which will make the cancer patient develop an immune response able to induce tumor regression. Clinical trials already under way in patients with malignant diseases may yield more definitive conclusions.
Daskalakis
G
G
First Department of Obstetrics and Gynaecology, Alexandra Hospital, University of Athens, Athens, Greece.
Thomakos
N
N
Papapanagiotou
A
A
Liakakos
T
T
Young
R L
RL
Antsaklis
A
A
D019496:Cancer Vaccines; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016032:Randomized Controlled Trials as Topic
D019496:Cancer Vaccines